Brown Advisory Inc Exact Sciences Corp Transaction History

Brown Advisory Inc

$71.5 Billion
Q2 2025

A detailed history of Brown Advisory Inc transactions in Exact Sciences Corp stock. As of the latest transaction made, Brown Advisory Inc holds 11,076 shares of EXAS stock, worth $703,326. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,076

Previous 5,258 110.65%

Holding current value

$703,326

Previous $227,000 159.03%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$40.31 - $58.08 $234,523 - $337,909	5,818 Added 110.65%	11,076 $588,000
Q1 2025 Apr 29, 2025	SELL	$43.04 - $58.51 $1,721 - $2,340	-40 Reduced 0.76%	5,258 $227,000
Q4 2024 Feb 14, 2025	SELL	$49.33 - $71.97 $56,334 - $82,189	-1,142 Reduced 17.73%	5,298 $297,000
Q3 2024 Nov 13, 2024	SELL	$42.43 - $70.83 $43,108 - $71,963	-1,016 Reduced 13.63%	6,440 $438,000
Q2 2024 Aug 14, 2024	SELL	$41.33 - $74.26 $28,600 - $51,387	-692 Reduced 8.49%	7,456 $315,000
Q1 2024 Apr 24, 2024	SELL	$56.27 - $73.77 $7,821 - $10,254	-139 Reduced 1.68%	8,148 $562,000
Q4 2023 Feb 08, 2024	SELL	$59.06 - $75.72 $87,940 - $112,747	-1,489 Reduced 15.23%	8,287 $613,000
Q3 2023 Oct 24, 2023	SELL	$65.94 - $99.04 $21,232 - $31,890	-322 Reduced 3.19%	9,776 $666,000
Q2 2023 Jul 31, 2023	SELL	$62.68 - $95.05 $33,533 - $50,851	-535 Reduced 5.03%	10,098 $948,000
Q1 2023 May 08, 2023	SELL	$47.19 - $70.77 $7,550 - $11,323	-160 Reduced 1.48%	10,633 $721,000
Q4 2022 Feb 13, 2023	SELL	$30.35 - $53.15 $19,879 - $34,813	-655 Reduced 5.72%	10,793 $534,000
Q3 2022 Nov 14, 2022	SELL	$31.97 - $49.37 $41,976 - $64,822	-1,313 Reduced 10.29%	11,448 $372,000
Q2 2022 Nov 14, 2022	SELL	$35.61 - $76.23 $52,631 - $112,667	-1,478 Reduced 10.38%	12,761 $502,000
Q2 2022 Sep 13, 2022	BUY	$35.61 - $76.23 $55,195 - $118,156	1,550 Added 11.96%	14,514 $572,000
Q2 2022 Aug 02, 2022	SELL	$35.61 - $76.23 $103,411 - $221,371	-2,904 Reduced 18.3%	12,964 $649,000
Q1 2022 Nov 14, 2022	SELL	$57.56 - $82.54 $15,829 - $22,698	-275 Reduced 1.89%	14,239 $995,000
Q1 2022 Sep 13, 2022	BUY	$57.56 - $82.54 $93,765 - $134,457	1,629 Added 11.44%	15,868 $1.11 Million
Q1 2022 May 09, 2022	SELL	$57.56 - $82.54 $147,008 - $210,807	-2,554 Reduced 15.21%	14,239 $1.02 Million
Q4 2021 Jan 27, 2022	SELL	$72.5 - $100.68 $111,505 - $154,845	-1,538 Reduced 8.39%	16,793 $1.31 Million
Q3 2021 Nov 12, 2021	SELL	$90.24 - $124.05 $1.46 Million - $2 Million	-16,138 Reduced 46.82%	18,331 $1.75 Million
Q2 2021 Jul 29, 2021	SELL	$93.66 - $139.27 $93,847 - $139,548	-1,002 Reduced 2.82%	34,469 $4.29 Million
Q1 2021 May 14, 2021	BUY	$116.57 - $155.01 $4.13 Million - $5.5 Million	35,471 New	35,471 $4.67 Million
Q2 2019 Aug 12, 2019	SELL	$89.51 - $118.04 $1.47 Million - $1.94 Million	-16,446 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$61.98 - $96.5 $391,031 - $608,818	-6,309 Reduced 27.73%	16,446 $1.43 Million
Q4 2018 Feb 13, 2019	SELL	$56.04 - $82.66 $760,518 - $1.12 Million	-13,571 Reduced 37.36%	22,755 $1.44 Million
Q3 2018 Nov 13, 2018	BUY	$48.29 - $80.6 $182,874 - $305,232	3,787 Added 11.64%	36,326 $2.87 Million
Q2 2018 Aug 10, 2018	BUY	$37.84 - $69.96 $965,109 - $1.78 Million	25,505 Added 362.6%	32,539 $1.95 Million
Q1 2018 Jun 28, 2018	BUY	$39.82 - $57.53 $2,349 - $3,394	59 Added 0.85%	7,034 $284,000
Q1 2018 May 14, 2018	BUY	$39.82 - $57.53 $25,126 - $36,301	631 Added 9.95%	6,975 $282,000
Q4 2017 Feb 12, 2018	SELL	$46.49 - $60.51 $67,828 - $88,284	-1,459 Reduced 18.7%	6,344 $334,000
Q3 2017 Nov 13, 2017	BUY	$37.05 - $47.12 $289,101 - $367,677	7,803	7,803 $368,000

Others Institutions Holding EXAS

# of Institutions

659

Shares Held

159M

Call Options Held

1.43M

Put Options Held

2.35M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $11.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brown Advisory Inc with notifications on news.

Account

Brown Advisory Inc Exact Sciences Corp Transaction History